澳優(01717.HK)料自家品牌配方奶粉產品第三季銷售額按年增逾30%
澳優(01717.HK)指,注意到公司股份之價格及成交量今天出現不尋常波動。經就合理查詢後,確認並不知悉任何導致股份價格及成交量出現有關波動之原因,亦不知悉任何必須公佈之內幕消息。
另外,董事會確認目前集團之財務及營運狀況保持理想,過去數年之收入增長預期將持續至截至2019年9月30日止三個月,主要源於集團之自家品牌配方奶粉產品之增長。基於目前取得之資料,預期集團自家品牌配方奶粉產品第三季之銷售額將按年增加超過30%。
目前,就殺人鯨資本的沽空報告所作的獨立審查第二階段現正按計劃進行。基於獨立審查目前之進度,獨立審查之第二階段預期將於今年10月完成。獨立審查委員會將於第二階段完成後審閱獨立審查之發現,並據此向董事會推薦應採取之適當行動。公司將於適當時候另行發表公告,向股東及潛在投資者提供有關獨立審查第二階段之進展及主要發現之最新資料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.